Investment and Product License includes licensing fee and development costs
Drug Development and Nutraceuticals Covered in JV.
EastGate to receive funding in tranches up to $5 million USD.
The Share Reserve with Transfer Agent has been cancelled and all remaining shares have been returned to EastGate Biotech.
The Kell Group Limited served as an agent for related-party advances.
Mandate also includes collaboration with local hospital for innovative Surgical and Anti-Aging procedures